ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年第一次临时股东会决议公告 | 2025-01-20 | Chinese | |
| 2025年第一次临时股东会法律意见书 | 2025-01-20 | Chinese | |
| 关于公司完成工商变更登记的公告 | 2025-01-06 | Chinese | |
| 第六届董事会第四次会议决议公告 | 2025-01-03 | Chinese | |
| 睿智医药科技股份有限公司董事会关于公司管理层收购事宜致全体股东的报告书 | 2025-01-03 | Chinese | |
| 第六届监事会第四次会议决议公告 | 2025-01-03 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
9 filings
| |||||
| 36043816 | 2025年第一次临时股东会决议公告 | 2025-01-20 | Chinese | ||
| 36043807 | 2025年第一次临时股东会法律意见书 | 2025-01-20 | Chinese | ||
| 36043794 | 关于公司完成工商变更登记的公告 | 2025-01-06 | Chinese | ||
| 36043782 | 第六届董事会第四次会议决议公告 | 2025-01-03 | Chinese | ||
| 36043771 | 睿智医药科技股份有限公司董事会关于公司管理层收购事宜致全体股东的报告书 | 2025-01-03 | Chinese | ||
| 36043758 | 第六届监事会第四次会议决议公告 | 2025-01-03 | Chinese | ||
| 36043739 | 睿智医药科技股份有限公司拟实施管理层收购所涉及的睿智医药科技股份有限公司股东全部权益价值项目资产评估报告 | 2025-01-03 | Chinese | ||
| 36042995 | 北京博星证券投资顾问有限公司关于睿智医药科技股份有限公司管理层收购之独立财务顾问报告 | 2025-01-03 | Chinese | ||
| 36042972 | 关于召开2025年第一次临时股东会的通知 | 2025-01-03 | Chinese | ||
|
2024
6 filings
| |||||
| 36042960 | 2024年第三次临时股东会法律意见书 | 2024-12-25 | Chinese | ||
| 36042947 | 2024年第三次临时股东会决议公告 | 2024-12-25 | Chinese | ||
| 36042938 | 关于全资子公司对外投资的进展公告 | 2024-12-16 | Chinese | ||
| 36042928 | 关于公司控股股东、董事长涉及诉讼的进展公告 | 2024-12-13 | Chinese | ||
| 36042920 | 关于2024年度向特定对象发行股票摊薄即期回报的影响与填补回报措施及相关主体承诺的公告 | 2024-12-13 | Chinese | ||
| 36042912 | 未来三年（2025年-2027年）股东分红回报规划 | 2024-12-13 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.